Product Description
p63 Antibody | 33-726 | ProSci
Host: Rabbit
Reactivity: Human
Homology: N/A
Immunogen: Recombinant partial human p53 protein was used as the immunogen for this p63 antibody.
Research Area: Cancer, Cell Cycle, Signal Transduction
Tested Application: Flow, IF, IHC-P
Application: Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 1-2 ug/ml
Immunohistochemistry (FFPE) : 1-2 ug/ml for 30 minutes at RT
The optimal dilution of the p63 antibody for each application should be determined by the researcher.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein A affinity chromatography
Clonality: Polyclonal
Clone: N/A
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: Tumor protein 63, p63, Chronic ulcerative stomatitis protein, CUSP, Keratinocyte transcription factor KET, Transformation-related protein 63, TP63, Tumor protein p73-like, p73L, p40, p51, TP63, KET, P63, P73H, P73L, TP73L
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S) . p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC) , with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC) , is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.